Avenue Therapeutics, a New York-based specialty pharmaceutical firm, is currently focused on developing and bringing revolutionary products to market for use in the acute/intensive care hospital setting. The company's lead product candidate is intravenous Tramadol, a synthetic dual-acting opioid designed to treat post-operative acute pain. Currently in Phase III clinical trials, Avenue Therapeutics is poised to make a significant impact in the field of pain management. The company, which was founded in 2015, is at the forefront of cutting-edge research in the pharmaceutical industry.
Avenue Therapeutics, Inc.'s ticker is ATXI
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 1-10 employees working at Avenue Therapeutics, Inc.
It is https://www.avenuetx.com/
Avenue Therapeutics, Inc. is in the Healthcare sector
Avenue Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Avenue Therapeutics, Inc.'s industry peers: